Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD. Roque DM, et al. Among authors: tymon rosario jr. Br J Cancer. 2024 Apr;130(6):1073. doi: 10.1038/s41416-024-02628-4. Br J Cancer. 2024. PMID: 38438590 Free PMC article. No abstract available.
Advances in antibody-drug conjugates for gynecologic malignancies.
Tymon-Rosario J, Gorman M, Richardson DL, Washington C, Santin AD. Tymon-Rosario J, et al. Curr Opin Obstet Gynecol. 2023 Feb 1;35(1):6-14. doi: 10.1097/GCO.0000000000000838. Epub 2022 Dec 8. Curr Opin Obstet Gynecol. 2023. PMID: 36484278 Review.
Targeted Therapies in the Treatment of Uterine Serous Carcinoma.
Tymon-Rosario JR, Gorman M, Santin AD. Tymon-Rosario JR, et al. Curr Treat Options Oncol. 2022 Dec;23(12):1804-1817. doi: 10.1007/s11864-022-01030-7. Epub 2022 Nov 30. Curr Treat Options Oncol. 2022. PMID: 36447064 Review.
Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu.
Yadav G, Roque DM, Bellone S, Manavella DD, Hartwich TMP, Zipponi M, Harold J, Tymon-Rosario J, Mutlu L, Altwerger G, Menderes G, Ratner E, Buza N, Hui P, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Alexandrov LB, Santin AD. Yadav G, et al. Among authors: tymon rosario j. Gynecol Oncol. 2022 Aug;166(2):351-357. doi: 10.1016/j.ygyno.2022.05.021. Epub 2022 May 28. Gynecol Oncol. 2022. PMID: 35641325
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
Tymon-Rosario JR, Manara P, Manavella DD, Bellone S, Hartwich TMP, Harold J, Yang-Hartwich Y, Zipponi M, Choi J, Jeong K, Mutlu L, Yang K, Altwerger G, Menderes G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Alexandrov LB, Santin AD. Tymon-Rosario JR, et al. Gynecol Oncol. 2022 Jul;166(1):117-125. doi: 10.1016/j.ygyno.2022.05.005. Epub 2022 May 20. Gynecol Oncol. 2022. PMID: 35599167
Immune checkpoint inhibitors for recurrent endometrial cancer.
Mutlu L, Harold J, Tymon-Rosario J, Santin AD. Mutlu L, et al. Among authors: tymon rosario j. Expert Rev Anticancer Ther. 2022 Mar;22(3):249-258. doi: 10.1080/14737140.2022.2044311. Epub 2022 Feb 24. Expert Rev Anticancer Ther. 2022. PMID: 35176955 Review.
49 results